Notch Therapeutics

Notch develops immune cell therapy developing a next-generation pipeline that is compatible and focuses on initial cancer cells. The company's proprietary T-cell production platform enables precision control of Notch signaling, which is required for T-cell development, by combining sophisticated product design with commercial-compatible processes. The ability to control notch signaling eliminates several critical limiting factors in cell therapy development and provides the ability to design and manufacture a consistent and limitless supply of therapeutic T cells.

Notch Therapeutics was established in 2018 and is headquartered in Toronto, Canada.

Notch Therapeutics headquartered in North America, operates in the Biotechnology, Health Care, Developer Platform sector. The company focuses on Biotechnology and has secured $6.1B in funding across 60 round(s). With a team of 101-250 employees, Notch Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - Notch Therapeutics, raised $15.5M. Discover more about their projects, partnerships, and impact on our platform.